Early Diagnostic Value of Novel Biomarkers for Breast Cancer Therapy-Related Cardiac Dysfunction
Authors' conclusion
Our study suggested that MPO was associated with both diagnostic biomarker profiles and mechanistic pathways in CTRCD pathogenesis.
Study context
- Population
- Breast cancer patients receiving cancer therapy
- Participants
- 917 patients12 studies
- Comparison
- Post-treatment vs pre-treatment biomarker levels; Myeloperoxidase (MPO) genetic instruments vs heart failure (HF) and cardiomyopathy
- Outcome
- Post-treatment changes in MPO, GDF-15, C-reactive protein (CRP), PLGF and Gal-3 and cancer therapy-related cardiac dysfunction (CTRCD) risk
- Follow-up
- Median 12 months
Methodological detailsPRISMA-compliant, two-sample Mendelian randomization (MR)
- PRISMA-compliant
- Two-sample MR
Pooled result
As reported in the abstract
Estimate (95% CI)P value
MPO (US patients)I2 = 72%
SMD 0.78(0.45–1.12)
P < 0.00001GDF-15I2 = 77%
SMD 0.64(0.24–1.05)
P = 0.002PLGFI2 = 95%
SMD 0.87(0.10–1.63)
P = 0.03CRPI2 = 18%
WMD 0.83(0.46–1.20)
P < 0.0001Hazard ratio (95% CI)P value
Elevated MPOCTRCD risk; I2 = 0%
1.30(1.10–1.54)
P = 0.002Further pooled results
MR: MPO and HF
| OR (95% CI) | P value | ||
|---|---|---|---|
| MPO | 1.06 (1.02–1.09) | P = 0.001 | |
| 0.512Odds ratio (log scale) |
MR: MPO and cardiomyopathy
| OR (95% CI) | P value | ||
|---|---|---|---|
| MPO | 1.09 (1.02–1.17) | P = 0.02 | |
| 0.512Odds ratio (log scale) |
- MR: MPO and HF: Heterogeneity in HF single nucleotide polymorphisms (SNPs): Cochran's Q = 61.63, P = 0.04
Original publication
Early Diagnostic Value of Novel Biomarkers for Breast Cancer Therapy-Related Cardiac Dysfunction. ESC Heart Fail. Published 17 September 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →